Wells Fargo & Company MN Boosts Stake in Sera Prognostics, Inc. (NASDAQ:SERA)

Wells Fargo & Company MN raised its position in Sera Prognostics, Inc. (NASDAQ:SERA) by 55.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 13,192 shares of the company’s stock after purchasing an additional 4,691 shares during the period. Wells Fargo & Company MN’s holdings in Sera Prognostics were worth $107,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jane Street Group LLC lifted its position in shares of Sera Prognostics by 24.8% during the third quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock worth $111,000 after purchasing an additional 2,826 shares during the last quarter. Pallas Capital Advisors LLC bought a new position in shares of Sera Prognostics during the fourth quarter worth about $113,000. Rhumbline Advisers lifted its position in shares of Sera Prognostics by 10.6% during the fourth quarter. Rhumbline Advisers now owns 36,101 shares of the company’s stock worth $294,000 after purchasing an additional 3,468 shares during the last quarter. Barclays PLC lifted its position in shares of Sera Prognostics by 321.6% during the third quarter. Barclays PLC now owns 39,450 shares of the company’s stock worth $308,000 after purchasing an additional 30,093 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Sera Prognostics by 5.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 81,228 shares of the company’s stock worth $661,000 after purchasing an additional 4,115 shares during the last quarter. 54.64% of the stock is owned by hedge funds and other institutional investors.

Sera Prognostics Stock Up 4.7%

Shares of NASDAQ SERA opened at $2.22 on Monday. The firm’s 50-day moving average price is $3.48 and its two-hundred day moving average price is $5.49. Sera Prognostics, Inc. has a 52-week low of $2.10 and a 52-week high of $9.91. The stock has a market capitalization of $83.61 million, a P/E ratio of -2.24 and a beta of 0.99.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.06 million. As a group, equities research analysts expect that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.